Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam (NASDAQ: BEAT) reported first quarter 2026 results and key milestones in its cardiac care platform.
The company signed first commercial partnerships with ClearCardio and Atelier Health, launched flagship sites in New York, Dallas, South Florida and Southern California, and advanced heart attack detection and 12-lead ECG patch pilot studies.
HeartBeam reported Q1 2026 R&D expenses of $2.4M, SG&A of $2.3M, and a net loss of $4.7M, with operating cash use down 19% year over year.
Cash was $2.0M on March 31, 2026, and an April 2026 equity offering raised $11.5M in gross proceeds.
HeartBeam (NASDAQ: BEAT) began a pilot study of its investigational on-demand 12-lead ECG patch in patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia.
The ~50-patient study compares a synthesized 12-lead ECG from the patch with a standard 12-lead ECG after exercise stress testing, targeting an ambulatory patch ECG market of about $2 billion with established reimbursement.
HeartBeam (NASDAQ: BEAT) announced a commercial agreement with Beverly Hills-based Atelier Health, expanding its initial launch footprint to four U.S. markets: New York metro, Dallas, South Florida, and Southern California.
The partnership adds a concierge practice led by physicians affiliated with Cedars-Sinai and furthers HeartBeam’s subscription-based commercialization approach and cable-free 3D ECG placement for home clinical-grade 12-lead synthesis.
HeartBeam (NASDAQ: BEAT) will host a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern to review first-quarter results for the period ended March 31, 2026 and provide updates on strategic initiatives.
Management will discuss a limited commercial launch for arrhythmia assessment, progress on an extended-wear patch, heart attack detection work, and AI initiatives. A press release will be issued before the call; a presentation and webcast will be available via the company investor relations site.
HeartBeam (NASDAQ: BEAT) closed an underwritten public offering on April 16, 2026 of 12,500,000 shares for $10.0 million gross proceeds. The offering was led by ClearCardio, company leadership, board members, existing investors, and institutional participants.
Net proceeds are intended to support commercialization of its FDA-cleared 12-lead synthesized ECG system, advance an extended-wear patch and heart attack detection work, enhance AI capabilities, and for working capital and general corporate purposes. Titan Partners acted as sole bookrunner; the offering was made under a Form S-3/A shelf registration (File No. 333-293307).
HeartBeam (NASDAQ: BEAT) priced an underwritten public offering of 12,500,000 shares for gross proceeds of $10.0 million, with a 30-day overallotment option for up to 1,875,000 additional shares. The offering is expected to close on or about April 16, 2026.
Proceeds are intended to support commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG, advance an extended-wear patch and heart-attack detection work, enhance AI capabilities, and for working capital and general corporate purposes.
HeartBeam (NASDAQ: BEAT) announced it is commencing an underwritten public offering of common stock on April 14, 2026. The company said proceeds are intended to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, develop an extended-wear patch and heart attack detection, enhance AI capabilities, and fund general corporate purposes.
The offering is being made from a shelf registration declared effective March 17, 2026, with Titan Partners as sole bookrunner; terms, size, and timing remain subject to market conditions.
HeartBeam (NASDAQ: BEAT) reported Q4 and full-year 2025 results and commercial progress. Key milestones include FDA 510(k) clearance (Dec 2025) for a cable-free synthesized 12-lead ECG, a first commercial partnership with ClearCardio, enrollment in the ALIGN-ACS pilot, and a working prototype of a 12-lead extended-wear ECG patch.
Financials: cash $4.4M at Dec 31, 2025; Q4 net loss $5.3M; full-year net loss $21.0M; R&D 2025 $13.5M. Management hosted a webcast March 12, 2026.
HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to co-develop and validate next‑generation AI‑ECG algorithms using HeartBeam’s 3D ECG platform.
The partnership aims to train AI on longitudinal, synthesized 12‑lead ECGs captured at home to enable personalized, clinically relevant cardiac assessments and expand clinical indications and reimbursement pathways.
HeartBeam (NASDAQ: BEAT) said management will attend investor and industry conferences in March 2026 to provide commercial-launch updates and product demonstrations.
Key events: Oppenheimer MedTech & Services (virtual) March 16-17 with a March 16 webcast; ROTH Conference (Dana Point) March 23-24; ACC.26 (New Orleans) March 28-30 with booth #209. The FDA-cleared HeartBeam System will be demoed and a working 12-lead ECG extended wear patch prototype (not FDA-approved) will be shown to physicians and partners.